Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by it to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sorrento Therapeutics Inc (Sorrento), formerly QuikByte Software Inc, is a clinical stage, antibody-centric, biopharmaceutical company. It focuses on the treatment of chronic cancer pain as well as immunology and infectious diseases. The companys immuno-oncology (I-O) portfolio comprises of a broad fully human antibody library (G-MAB), clinical stage chimeric antigen receptor-T cells (CAR-T), intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir). Sorrento provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. It works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
Sorrento Therapeutics Inc Key Recent Developments
Jan 14,2019: Scilex Announces ZTlido Insurance Coverage for ~100 Million Insured Lives(1)
Jan 14,2019: Scilex Announces Addition of ZTlido to Express Scripts National Formularies
Nov 08,2018: Sorrento Therapeutics closes five-year term loan financing for up to $150 million
Nov 07,2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases
Nov 01,2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sorrento Therapeutics Inc (Sorrento), formerly QuikByte Software Inc, is a clinical stage, antibody-centric, biopharmaceutical company. It focuses on the treatment of chronic cancer pain as well as immunology and infectious diseases. The companys immuno-oncology (I-O) portfolio comprises of a broad fully human antibody library (G-MAB), clinical stage chimeric antigen receptor-T cells (CAR-T), intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir). Sorrento provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. It works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
Sorrento Therapeutics Inc Key Recent Developments
Jan 14,2019: Scilex Announces ZTlido Insurance Coverage for ~100 Million Insured Lives(1)
Jan 14,2019: Scilex Announces Addition of ZTlido to Express Scripts National Formularies
Nov 08,2018: Sorrento Therapeutics closes five-year term loan financing for up to $150 million
Nov 07,2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases
Nov 01,2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
TABLE OF CONTENTS
List of Tables
List of Figures
Section 1 - About the Company
Sorrento Therapeutics Inc - Key Facts
Sorrento Therapeutics Inc - Key Employees
Sorrento Therapeutics Inc - Key Employee Biographies
Sorrento Therapeutics Inc - Major Products and Services
Sorrento Therapeutics Inc - History
Sorrento Therapeutics Inc - Company Statement
Sorrento Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 Company Analysis
Company Overview
Sorrento Therapeutics Inc - Business Description
Sorrento Therapeutics Inc - Corporate Strategy
Sorrento Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sorrento Therapeutics Inc - Strengths
Sorrento Therapeutics Inc - Weaknesses
Sorrento Therapeutics Inc - Opportunities
Sorrento Therapeutics Inc - Threats
Sorrento Therapeutics Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sorrento Therapeutics Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Nov 08, 2018: Sorrento Therapeutics closes five-year term loan financing for up to $150 million
Nov 07, 2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases
Nov 01, 2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Sep 27, 2018: Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018
Sep 10, 2018: Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido Pain Medication
Jul 05, 2018: Sorrento buys Kimberly-Clarks Sofusa lymphatic delivery platform
Apr 23, 2018: Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on Unite to Cure
Mar 28, 2018: Sorrento Therapeutics Chairman/CEO update to stockholders
Mar 19, 2018: Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018
Feb 05, 2018: Sorrento Therapeutics Chairman/CEO letter to stockholders
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List Of Tables
Sorrento Therapeutics Inc, Key Facts
Sorrento Therapeutics Inc, Key Employees
Sorrento Therapeutics Inc, Key Employee Biographies
Sorrento Therapeutics Inc, Major Products and Services
Sorrento Therapeutics Inc, History
Sorrento Therapeutics Inc, Subsidiaries
Sorrento Therapeutics Inc, Joint Venture
Sorrento Therapeutics Inc, Key Competitors
Sorrento Therapeutics Inc, Ratios based on current share price
Sorrento Therapeutics Inc, Annual Ratios
Sorrento Therapeutics Inc, Annual Ratios (Cont...1)
Sorrento Therapeutics Inc, Interim Ratios
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sorrento Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List Of Figures
Sorrento Therapeutics Inc, Performance Chart (2013 - 2017)
Sorrento Therapeutics Inc, Ratio Charts
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
RELATED REPORTS
Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Sorrento Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,
View ReportAnika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2021 Update
Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical and veterinary applications. Its major
View ReportChinook Therapeutics Inc (KDNY) - Financial and Strategic SWOT Analysis Review
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
